Clinical trials: Atopic Disorders
Asthma
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in…
- Trial name
- ARIA (NCT02821416)
- Testing
- Benralizumab
- Where
- 6 sites in Canada
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Atopic Dermatitis, Eczema
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds.
- Trial name
- NCT00076375
- Testing
- Nanocrystalline silver cream (NPI)
- Where
- 19 sites in United States
- Volunteers
- 180 people
- Sponsor
- Nucryst Pharmaceuticals
Atopic Dermatitis
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic…
- Trial name
- NCT03916081
- Testing
- Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream
- Where
- 20 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis, Healthy Volunteers
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
The purpose of this study is to evaluate microneedle-based collection of dermal interstitial skin fluid (dISF) in healthy participants and atopic dermatitis (AD) participants
- Trial name
- NCT06934980
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated
Dermatitis, Atopic
A Study of LY3471851 in Participants With Eczema
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema.
- Trial name
- NCT04081350
- Testing
- LY3471851
- Where
- 20 sites in United States
- Volunteers
- 48 people
- Sponsor
- Nektar Therapeutics
Moderate/Severe Atopic Dermatitis
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.
- Trial name
- NCT01745159
- Testing
- tacrolimus
- Where
- 4 sites in China
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma China, Inc.
Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel…
- Conditions
- Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic
- Trial name
- NCT04037891
- Testing
- rVA576
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 12 people
- Sponsor
- AKARI Therapeutics
Atopic Dermatitis
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol Topical Oil is applied to pediatric subjects with…
- Trial name
- NCT03847389
- Testing
- Clobetasol propionate 0.05% Topical Oil
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hill Dermaceuticals, Inc.
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD.
- Trial name
- NCT05650320
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Healthy Volunteer, Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B).
- Trial name
- AURA-AD (NCT07527923)
- Testing
- REGN20423
- Where
- 7 sites in United States, Belgium
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
Atopic Dermatitis, Type 1 Hypersensitivity
Allergic Disease Onset Prevention Study
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1…
- Trial name
- adored (NCT05003804)
- Testing
- STMC-103H
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.
Atopic Dermatitis
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
- Trial name
- NCT00125333
- Testing
- NF-kappaB Decoy
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- Anesiva, Inc.
Dermatitis, Atopic Dermatitis
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT02087943
- Testing
- Apremilast
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 191 people
- Sponsor
- Amgen
Atopic Dermatitis (AD)
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult patients (18-75 years) with moderate to severe AD suitable for systemic…
- Trial name
- NCT07175233
- Testing
- SIM0278 injection
- Where
- 2 sites in China
- Volunteers
- 184 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Healthy, Dermatitis, Atopic
First in Human of Single and Multiple Doses of MOR106
This is a randomized, double-blind, placebo-controlled, dose-escalation, phase I study for the assessment of safety, tolerability and pharmacokinetics of single ascending doses of MOR106 in healthy male subjects and multiple…
- Trial name
- NCT02739009
- Testing
- MOR106 single ascending doses, intravenous, MOR106 multiple ascending doses, intravenous
- Where
- 4 sites in Belgium, Hungary and 2 more
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy…
- Trial name
- NCT07235384
- Testing
- ZL-1503
- Where
- 12 sites in Australia, China and 1 more
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Atopic Dermatitis
A Study Evaluating TRIV-573 in Atopic Dermatitis
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
- Trial name
- NCT07782333
- Testing
- TRIV-573
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Triveni Bio
Atopic Dermatitis
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with…
- Trial name
- ATLAS (NCT05155085)
- Testing
- AK002
- Where
- 55 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Allakos Inc.